1324 related articles for article (PubMed ID: 30426297)
1. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
4. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
[TBL] [Abstract][Full Text] [Related]
5. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
6. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
8. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
9. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
[TBL] [Abstract][Full Text] [Related]
10. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
11. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
12. Mucosal healing and anti TNFs in IBD.
van Assche G; Vermeire S; Rutgeerts P
Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
[TBL] [Abstract][Full Text] [Related]
13. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
14. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.
Yoshihara T; Shinzaki S; Kawai S; Fujii H; Iwatani S; Yamaguchi T; Araki M; Hiyama S; Inoue T; Hayashi Y; Watabe K; Iijima H; Takehara T
Inflamm Bowel Dis; 2017 Dec; 23(12):2172-2179. PubMed ID: 28945638
[TBL] [Abstract][Full Text] [Related]
15. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
16. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.
Boland K; Greener T; Kabakchiev B; Stempak J; Tessolini J; Li R; Soriano J; Croitoru K; Nguyen G; Steinhart AH; Weizman AV; Silverberg MS
Inflamm Bowel Dis; 2020 Apr; 26(5):766-773. PubMed ID: 31676891
[TBL] [Abstract][Full Text] [Related]
17. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
20. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
